Reduction in breast cancer mortality is attributed to the combination of earlier breast cancer detection through mammography screening and substantial improvements in breast cancer treatment ([@bib10]; [@bib18]; [@bib12]).

Screening mammograms can be assessed in several ways, for example, by single reading or double reading by certified screening radiologists. European guidelines consider double reading by radiologists as the gold standard for the assessment of screening mammograms, as this screening strategy significantly increases the cancer detection rate when compared with single reading ([@bib8]; [@bib3]). In most programmes, including the Dutch nationwide breast cancer screening programme, independent double reading rather than blinded double reading is used for the assessment of screening mammograms. We recently compared these two reading strategies and found that blinded double reading increased the sensitivity of breast cancer detection, at the expense of an increased referral rate and decreased positive predictive value (PPV) of referral ([@bib11]). However, the influence of replacement of non-blinded by blinded double reading on the use of diagnostic resources at the workup of screen-positive women is unknown. We therefore compared the utilisation of breast imaging and biopsy techniques in women referred at blinded or non-blinded double reading in a population-based screening mammography programme in the south of the Netherlands.

Materials and methods
=====================

Study population
----------------

We used the information of respectively 42 996 and 44 491 full-field digital screens that had been double read, either in a non-blinded or blinded manner between July 2009 and July 2011 ([@bib11]).

Screening procedure and referral
--------------------------------

Details of the nationwide and local breast cancer screening programme have been described previously ([@bib5]; [@bib14]; [@bib11]). In brief, free biennial screening mammography is offered to women aged 50--75 years. Before each screening examination, the woman completes a short questionnaire with questions about any previous breast surgery or breast malignancy and the use of hormone replacement therapy. Screening mammograms were double read in either a blinded (second reader was not informed about the first reader\'s decision) or non-blinded (second reader was informed about the first reader\'s decision). This reading strategy was alternated on a monthly basis. Mammograms of previous screening rounds were always available for comparison.

Women with a screening Breast Imaging Reporting and Data System (BI-RADS) category 0, 4 or 5 were referred to a dedicated breast unit ([@bib2]).

Diagnostic work-up and follow-up of referred women
--------------------------------------------------

A total of 15 regional and university hospitals were involved in the assessment of screen-positive women. The type of further diagnostic evaluation depended on the workup protocols of the various hospitals and could include breast tomosynthesis, (3D) breast ultrasonography, magnetic resonance imaging, ultrasound-guided fine-needle aspiration biopsy (FNAB) or core needle biopsy (CNB), stereotactic CNB (SCNB) or surgical excision biopsy. BI-RADS 0 lesions received additional imaging and biopsy if necessary. BI-RADS 4 and 5 lesions were routinely biopsied, whereas BI-RADS 3 lesions were either biopsied or followed up. Data on mammographic breast density and family history of breast cancer were extracted from the radiological and surgical records, respectively. The follow-up period of all referred women was 2 years (until the next biennial screen).

Statistical analysis
--------------------

Descriptive statistics were performed using Statistical Package for Social Science 17.0 (SPSS Inc. Chicago, IL, USA). A Fisher\'s exact test or *χ*^2^-test was used to test differences in biopsy rates and workup procedures at non-blinded and blinded double reading.

Results
=======

Overall workup procedures after referral
----------------------------------------

A total of 1235/42 996 (2.9%) and 1474/44 491 (3.3%) women had been referred, respectively, at non-blinded and blinded double reading. Baseline characteristics for screened and referred women were comparable for the two reading strategies ([Table 1](#tbl1){ref-type="table"}). At both reading strategies, workup consisted of additional breast-imaging procedures only in about half of referrals, whereas the other half underwent a combination of additional breast imaging plus biopsy (*P*=0.164; [Table 2](#tbl2){ref-type="table"}). The vast majority of biopsy procedures in both groups consisted of either CNB or SCNB, whereas \<3% of referred women underwent FNAB and surgical biopsy was hardly used for diagnostic purposes. The distribution of various combinations of assessment at workup was also comparable, but the ultrasound-guided CNB rate and SCNB rate per 1000 screens were lower at non-blinded than at blinded double reading (6.0 *vs* 7.5, *P*=0.008 and 6.6 *vs* 8.1, *P*=0.009, respectively).

Work-up in false-positive referrals
-----------------------------------

A total of 951 (77.0% of referrals) and 1149 (80.0% of referrals) women experienced a false-positive referral at non-blinded and blinded double reading, respectively ([Table 3](#tbl3){ref-type="table"}). The distribution of type of assessment differed between both groups, with a larger proportion of women evaluated by additional imaging only at non-blinded double reading (65.0% *vs* 60.7%, *P*=0.046) and a larger proportion of CNB procedures at blinded double reading (9.9% *vs* 6.5%, *P*=0.005). Almost all diagnostic surgical biopsies following referral had been performed in false-positive cases, but the false-positive surgical biopsy rate was still very low at both reading strategies (0.37 and 0.34 per 1000 screens at non-blinded and at blinded double reading, respectively). The CNB rate (*P*\<0.001) and SCNB rate (*P*=0.013) per 1000 screens were higher at blinded than at non-blinded reading.

Overall biopsy rates and PPV of biopsy
--------------------------------------

The two reading strategies showed comparable PPV of biopsy (46.3% *vs* 41.9% at non-blinded and blinded double reading, respectively, *P*=0.103; [Table 4](#tbl4){ref-type="table"}). Both the overall biopsy rate and benign biopsy rate per 1000 screens were higher at blinded double reading (17.4 *vs* 14.3, *P*\<0.001 and 10.1 *vs* 7.7, *P*\<0.001, respectively), as well as the proportion of women who underwent biopsy as part of a false-positive referral (39.3% *vs* 34.7%, *P*=0.032).

Discussion
==========

We found that blinded double reading resulted in significantly higher CNB and SCNB rates than non-blinded double reading, as well as a significantly higher benign biopsy rate. A larger proportion of women at benign work-up were evaluated merely by additional imaging at non-blinded double reading, whereas a larger fraction of referrals underwent CNB procedures at blinded double reading. The PPV of biopsy was comparable for both reading strategies.

The current study included screens during the first round of digital screening in the Netherlands. We found a biopsy rate of 14.3 per 1000 screens after non-blinded double reading and 17.4 per 1000 screens after blinded double reading. To our knowledge, data of biopsy rates after blinded double reading have not been reported previously. The biopsy rates we observed after non-blinded double reading are comparable to those of a Norwegian (61/4009) and Irish (470/35204) study during the first round of digital mammography ([@bib16]; [@bib9]).

In a Dutch study, increased detection of lesions presenting as microcalcifications during the transition from screen-film to digital screening mammography resulted in an almost fourfold increase in SCNB per 1000 screened women ([@bib14]). The further intensified use of SCNB at blinded double reading may have a great impact on daily practice of regional breast clinics, as it is much more time consuming than conventional breast imaging or ultrasound-guided biopsy.

Among women with benign work-up, a larger fraction was evaluated simply by additional imaging at non-blinded double reading, whereas a larger fraction at blinded double reading also underwent CNB procedures. The higher referral rate at blinded double reading results in higher costs of the diagnostic procedures in the hospital, which will rise even further as a larger fraction of referrals is evaluated by CNB in addition to breast imaging at blinded double reading.

The higher biopsy rates at blinded double readings was accompanied by an increased cancer detection rate, which resulted in a comparable PPV of biopsy of \>40% at both reading strategies. This PPV is within the range of those found in other European programmes and higher than those observed in the United States ([@bib16]; [@bib19]; [@bib7]).

It remains a question of debate whether false-positive referrals, which received additional imaging or biopsy, have uniformly decreased odds of attending subsequent routine screening rounds ([@bib4]; [@bib15]; [@bib13]). Many of the women with false-positive screening results experience distress ([@bib17]), which may last for up to 3 years after a false-positive screen and is related to the invasiveness of the assessment ([@bib1]). It is therefore important to keep the number of benign biopsies as low as possible.

Our study has certain limitations. The study population consisted of women who attended the screening programme during the transition from screen-film to digital screening mammography. Therefore, the majority of subsequent screens were compared with previously obtained screen-film mammograms. Data on screening outcome after the transition to digital screening mammography are sparse and there are no studies available that compare the use of diagnostic work-up modalities during and after the transition. All screening examinations in our study comprised two-view mammography of both breasts, including a medio-lateral oblique view and a cranio-caudal view. Recent studies have shown that the addition of breast tomosynthesis to digital mammography improves the cancer detection rate in mammography screening and may reduce false-positive referrals ([@bib6]). Breast tomosynthesis, however, has not yet been implemented in the Dutch mammography screening programme.

In summary, we conclude that blinded double reading resulted in significantly higher overall and benign biopsy rate than non-blinded double reading. Although an increased screening sensitivity at blinded double reading has been reported, the negative side effect of higher biopsy rates should be taken into account when adopting this reading strategy.
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###### Baseline characteristics of women screened and referred at non-blinded and blinded double reading

                                                                        **Screened population**                    **Referred women**                              
  -------------------------------------------------------------------- ------------------------- ---------------- -------------------- ------------- ------------- ------
  Age distribution, no (%)                                                                                                0.49                                      0.91
   50--59                                                                    22 704 (52.8)        23 469 (52.7)                         653 (52.9)    778 (52.8)      
   60--69                                                                    14 537 (33.8)        14 949 (33.6)                         417 (33.8)    491 (33.3)      
   70--75                                                                     5755 (13.4)          6073 (13.6)                          165 (13.3)    205 (13.9)      
  Previous breast surgery, no (%)                                                                                         0.58                                      0.20
   Yes                                                                        3354 (7.8)            3516 (7.9)                          129 (10.4)    177 (12.0)      
   No                                                                        39 642 (92.2)        40 975 (92.1)                         1106 (89.6)   1297 (88.0)     
  Hormone replacement therapy, no. (%)                                                                                    0.74                                      0.82
   Yes                                                                        2064 (4.8)            2157 (4.8)                           55 (4.5)      63 (4.3)       
   No                                                                        40 932 (95.2)        42 334 (95.2)                         1180 (95.5)   1411 (95.7)     
  Family history of breast cancer[a](#t1-fn1){ref-type="fn"}, no (%)         Not available        Not available                                                     0.59
   Yes                                                                                                                                  149 (12.1)    168 (11.4)      
   No                                                                                                                                   1086 (87.9)   1306 (88.6)     
  Screening round, no (%)                                                                                                 0.85                                      0.15
   Initial screen                                                             4784 (11.1)          4968 (11.2)                          309 (25.0)    334 (22.7)      
   Subsequent screen                                                         38 212 (88.9)        39 523 (88.8)                         926 (75.0)    1140 (77.3)     
  Mammographic breast density                                                Not available        Not available                                                     0.83
   0--50%                                                                                                                               1014 (82.1)   1215 (82.4)     
   \>50%                                                                                                                                221 (17.9)    259 (17.6)      
  Lesion abnormality at latest screen, no (%)                               Not applicable        Not applicable                                                    0.34
   Suspicious mass                                                                                                                      718 (58.1)    827 (56.1)      
   Suspicious microcalcifications                                                                                                       334 (27.0)    445 (30.2)      
   Suspicious mass with microcalcifications                                                                                              85 (6.9)      95 (6.4)       
   Asymmetry                                                                                                                             22 (1.8)      28 (1.9)       
   Architectural distortion                                                                                                              72 (5.8)      78 (5.3)       
   Other mammographic abnormality                                                                                                         4 (0.3)       1 (0.1)       

At least one first-degree relative with a diagnosis of breast cancer before the age of 50 years or at least two second-degree relatives with breast cancer.

###### Non-blinded *vs* blinded double reading at screening mammography: assessment following referral

                                                                               **Proportion**   **Rate (per 1000 screened women)**                                       
  --------------------------------------------------------------------------- ---------------- ------------------------------------ ----- -------- ------- ------ ------ -------
  No further assessment                                                              3                        (0.2)                   0    \(0\)     ---    0.1     0      ---
  Additional breast imaging                                                         618                       (50.0)                 698   (47.4)   0.164   14.4   15.7   0.110
  Additional breast imaging + FNAB                                                   29                       (2.3)                  36    (2.4)    0.873   0.7    0.8    0.465
  Additional breast imaging + CNB                                                   259                       (21.0)                 333   (22.6)   0.310   6.0    7.5    0.008
  Additional breast imaging + SCNB                                                  285                       (23.1)                 362   (24.6)   0.368   6.6    8.1    0.009
  Additional breast imaging + FNAC + CNB/SCNB[a](#t2-fn2){ref-type="fn"}             16                       (1.3)                  18    (1.2)    0.862   0.4    0.4    0.808
  Additional breast imaging + CNB/FNAB/SCNB[b](#t2-fn3){ref-type="fn"} + SB          16                       (1.3)                  14    (0.9)    0.392   0.4    0.3    0.646
  Additional breast imaging + CNB +SCNB                                              8                        (0.6)                  12    (0.8)    0.614   0.2    0.3    0.413
  Additional breast imaging + SB                                                     1                        (0.1)                   1    (0.1)     ---     0      0      ---

Abbreviations: CNB=core needle biopsy; FNAB=fine needle aspiration biopsy; SB=surgical (open) biopsy; SCNB=stereotactic CNB.

CNB and/or SCNB.

CNB and/or FNAB and/or SCNB.

###### Non-blinded *vs* blinded double reading at screening mammography: assessment at false positive referral

                                                                               **Proportion**   **Rate (per 1000 screened women)**                                       
  --------------------------------------------------------------------------- ---------------- ------------------------------------ ----- -------- ------- ------ ------ ---------
  No further assessment                                                              3                        (0.3)                   0    \(0\)     ---    0.1     0       ---
  Additional breast imaging                                                         618                       (65.0)                 698   (60.7)   0.046   14.4   15.7    0.110
  Additional breast imaging + FNAB                                                   28                       (2.9)                  35    (3.0)    0.892   0.7    0.8     0.455
  Additional breast imaging + CNB                                                    62                       (6.5)                  114   (9.9)    0.005   1.4    2.6    \<0.001
  Additional breast imaging + SCNB                                                  200                       (21.0)                 261   (22.7)   0.353   4.7    5.9     0.013
  Additional breast imaging + FNAC + CNB/SCNB[a](#t3-fn2){ref-type="fn"}             16                       (1.7)                  15    (1.3)    0.476   0.4    0.3     0.783
  Additional breast imaging + CNB/FNAB/SCNB[b](#t3-fn3){ref-type="fn"} + SB          16                       (1.7)                  14    (1.2)    0.372   0.4    0.3     0.646
  Additional breast imaging + CNB +SCNB                                              8                        (0.8)                  11    (1.0)    0.780   0.2    0.2     0.539
  Additional breast imaging + SB                                                     0                        \(0\)                   1    (0.1)     ---     0      0       ---

Abbreviations: CNB=core needle biopsy; FNAB=fine needle aspiration biopsy; SB=surgical (open) biopsy; SCNB=stereotactic CNB.

CNB and/or SCNB.

CNB and/or FNAB and/or SCNB.

###### Biopsy rates and PPVs of biopsy at non-blinded and blinded double reading of screening mammograms

                                         **Non-blinded double reading**   **Blinded double reading**   ***P*****-value**
  ------------------------------------- -------------------------------- ---------------------------- -------------------
  Assessment at referral                                                                                     0.129
   Biopsy, %                                    49.7 (614/1235)                52.6 (776/1474)                  
   No biopsy, %                                 50.3 (621/1235)                47.4 (698/1474)                  
  Biopsy rate per 1000 screens                 14.3 (614/42 996)              17.4 (776/44 491)             \<0.001
  PPV of biopsy, %                               46.3 (284/614)                 41.9 (325/776)               0.103
  False-positive referral                                                                                    0.032
   Biopsy, %                                     34.7 (330/951)                39.3 (451/1149)                  
   No biopsy, %                                  65.3 (621/951)                60.7 (698/1149)                  
  Benign biopsy rate per 1000 screens           7.7 (330/42 996)              10.1 (451/44 491)             \<0.001

Abbreviation: PPV=positive predictive value.
